Skip to content
Strength & muscleResearch article3 min read

Sarcopenia is more than an old-age muscle problem: review links nerves, heart and metabolism

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Sarcopenia as a Multisystem Disorder-Connections with Neural and Cardiovascular Systems-A Related PRISMA Systematic Literature Review. · Life (Basel, Switzerland) · 2026 · Original paper ↗

Key takeaway

A systematic review of 42 articles published between January 2023 and December 2024 (plus 11 added studies) describes sarcopenia as a multifactorial condition involving mitochondria, nerve-muscle junctions, inflammation and hormones, with rehabilitation the most effective approach. It is a narrative summary without pooled results, so it cannot say how big any effect is.

Study design

Research article

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

Sarcopenia, the loss of muscle mass and function, has long been treated as a disease of old age, but it is increasingly seen in the general population and has neuromuscular, cardiovascular and metabolic roots. The authors set out to summarize recent evidence on its mechanisms, diagnosis and management.

Who and how

Systematic literature review following the Preferred Reporting Items for Systematic Reviews (PRISMA) method. A search of major international databases identified studies published between January 2023 and December 2024, and 42 articles were kept according to prespecified criteria. The authors then added 11 further studies they considered highly relevant. The abstract does not name the databases, the study designs included or any quality assessment.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    The literature describes sarcopenia as arising from many overlapping processes: mitochondrial dysfunction, degeneration of the neuromuscular junction (NMJ), chronic inflammation, anabolic resistance, endocrine and metabolic dysregulation, altered motor-unit remodeling and molecular changes.
  2. 2
    Diagnosis focuses on functional tests, especially muscle strength and physical performance. Imaging and new circulating biomarkers add precision in specific situations.
  3. 3
    Rehabilitation is described as one of the most effective treatment approaches. Nutritional optimization and drugs that modulate the renin-angiotensin system look promising only in specific patient subsets.

Limits & uncertainty

  1. 1
    The 11 extra studies were chosen by the authors for relevance rather than found by the prespecified search, which may tilt the picture toward their own view.
  2. 2
    The abstract reports no pooled effect sizes, so statements such as 'most effective' and 'promising' are qualitative judgments across mixed study types.
  3. 3
    Only studies from a two-year window (2023 to 2024) were searched, so earlier key trials may not be represented.
  4. 4
    This reading is based on the abstract only.

What to take from it

The review supports the view that keeping muscle strength and function over the years involves more than aging: nerves, circulation, inflammation and metabolism all play a part, and resistance-style rehabilitation is the best-supported response. It does not give specific doses or drug recommendations. Anyone worried about muscle loss should have it assessed by a clinician.

Reading your own data

The most practical personal measures are grip strength, sit-to-stand time or repetitions, and walking speed, all of which the review treats as core diagnostic ideas. Repeat them under the same conditions and follow your own trend rather than a single day's result.

How to read this evidence

The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background

Sarcopenia, which has traditionally been considered to be an exclusively geriatric syndrome, has an increased frequency within the general population and fosters interest in its complex neuromuscular, cardiovascular, and metabolic basis. The current systematic review, adopting the recognized Preferred Reporting Items for Systematic Reviews (PRISMA) methodology, seeks to highlight current evidence on the underlying mechanisms as well as approaches to sarcopenia diagnosis and management.

Methods

A comprehensive search of major international databases identified studies published between January 2023 and December 2024, from which 42 articles were retained according to prespecified criteria. To further enrich the present work, eleven additional studies of high relevance were included.

Results

The selected literature describes sarcopenia's multifactorial pathophysiology, including mitochondrial dysfunction, neuromuscular junction (NMJ) degeneration, chronic inflammation, anabolic resistance, endocrine and metabolic dysregulation, altered motor-unit remodeling, and molecular alterations. Diagnostic methods focus on functional assessments, especially muscle strength and physical performance. In addition, imaging techniques and new circulating biomarkers enhance precision in specific situations. Over the years, rehabilitation has proven to be one of the most effective therapeutic approaches. Complementary strategies, ranging from nutritional optimization to pharmacologic modulation of the renin-angiotensin system, show promise in specific patient subsets.

Discussion and conclusions

As supported by the works collected within the current study, future approaches will need to consider sarcopenia as a multifactorial disease that goes beyond aging.

Sources & attribution

Sarcopenia as a Multisystem Disorder-Connections with Neural and Cardiovascular Systems-A Related PRISMA Systematic Literature Review.

Popescu C, Aurelian SM, Mirea A, Munteanu C, Vlădulescu-Trandafir AI, Anghelescu A, Oancea C, Andone I, Spînu A, Suciu AV, Stoica SI, Gîdei SM, Alecu VM, Gîță CD, Pop NL, Ciobanu V, Onose G.

Life (Basel, Switzerland) · 2026-01-01

DOI: 10.3390/life16010068 ↗PubMed · 41598223 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Overview of reviews

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

In-depth explainersRead study →
·Trial meta-analysis

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

In-depth explainersRead study →
·Observational meta-analysis

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

In-depth explainersRead study →
·Trial meta-analysis

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

In-depth explainersRead study →
Strength & muscle →